Loading...

Preprints

Prenylation controls proliferation in human pluripotent stem cell-derived cardiomyocytes

Batho CA, Reid JD, Robinson HR, Szappanos HC, Devilée LA, Hoyte SM, Johnston RL, Ziegman R, Hassan S, Soday L, Fitzsimmons RL, Foster SR, Ng DCH, Tate E, Porrello ER, Parker BL, Mills RJ, Hudson JE.
Preprint from
bioRxiv
3 July 2024
PPR
PPR876493
Abstract
Induction of cardiomyocyte proliferation to replace damaged heart tissue is a promising therapeutic approach. A recent drug screen revealed that cardiomyocytes require the mevalonate pathway for proliferation, although the specific mechanisms are unknown. In this study, we use human pluripotent stem cell-derived cardiomyocytes and cardiac organoids to further interrogate the role of the mevalonate pathway in cardiomyocyte proliferation. Chemical and genetic perturbations of the mevalonate pathway indicated that the post-translational modification, prenylation, regulates cardiomyocyte proliferation. We use prenyl probes and mass spectrometry to identify a catalogue of 40 prenylated proteins in human cardiac cells, including proteins where prenylated function had not yet been investigated. We show that multiple prenylated proteins control cardiomyocyte proliferation including RRAS2 and NAP1L4. We demonstrate that prenylation has differential effects on distinct proteins, with RRAS2 prenylation controlling membrane localization and NAP1L4 prenylation regulating cardiomyocyte mitosis and centrosome homeostasis. Together, these data show that protein prenylation is required for cardiomyocyte proliferation through multiple targets and these processes may need to be re-activated for cardiac regeneration.